Physician profile
Jackson Cooper
NPI 1043056757
$5,907.73
in general payments reported to CMS, 2019-2025
17 companies · $4,790 in 2025
The $4,790 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,117 · 2025: $4,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600 · Travel and Lodging: $1,228 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.27 |
| Travel and Lodging | $1,228.47 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,261.71 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $1,003.68 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $690.39 | 2024-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $562.05 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $277.85 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.01 | 2024-2025 | Ofev, Jascayd |
| Verona Pharma, INC. | $218.35 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $173.43 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $151.16 | 2024-2025 | Glassia |
| Merck Sharp & Dohme LLC | $79.32 | 2025 | Zerbaxa |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Ambu INC. | $34.09 | 2025 | |
| Baxter Healthcare | $33.03 | 2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $24.84 | 2025 | Tyvaso |
| Insmed, INC. | $16.93 | 2025 | Arikayce |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $16.53 | 2024 | Yupelri |
| Amgen INC. | $15.37 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.